PDF(Pubmed)
Abstract：
BACKGROUND: Patients with differentiated thyroid cancer (DTC) are referred to radioactive 131I (RAI) therapy and post-therapy 131I whole-body scintigraphy (WBS) to identify local and/or remote metastases. Positron emission tomography (PET)/computed tomography (CT) imaging with 18F-fluoro-D-glucose (FDG) or 18F-sodium fluoride (NaF) may also be used with these patients for the evaluation of bone metastases. We compared the role of 18F-NaF PET/CT and 18F-FDG-PET/CT in patients with DTC and documented bone metastases at post-therapy WBS.
METHODS: Ten consecutive DTC patients with iodine avid bone metastasis at post-therapy WBS referred to 18F-NaF PET/CT and 18F-FDG PET/CT were studied. The findings of the three imaging procedures were compared for abnormal detection rates and concordance.
RESULTS: At post-therapy 131I WBS, all patients had skeletal involvement with a total of 21 bone iodine avid lesions. At 18F-FDG PET/TC, 19 bone lesions demonstrated increased tracer uptake and CT pathological alterations, while 2 lesions did not show any pathological finding. At 18F-NaF PET/CT, the 19 bone lesions detected at 18F-FDG PET/TC also demonstrated abnormal tracer uptake, and the other 2 bone iodine avid foci did not show any pathological finding.
CONCLUSIONS: In patients with DTC, 18F-NaF PET/CT did not obtain more information on the metastatic skeletal involvement than post-therapy 131I WBS and 18F-FDG PET/CT.
METHODS: Ten consecutive DTC patients with iodine avid bone metastasis at post-therapy WBS referred to 18F-NaF PET/CT and 18F-FDG PET/CT were studied. The findings of the three imaging procedures were compared for abnormal detection rates and concordance.
RESULTS: At post-therapy 131I WBS, all patients had skeletal involvement with a total of 21 bone iodine avid lesions. At 18F-FDG PET/TC, 19 bone lesions demonstrated increased tracer uptake and CT pathological alterations, while 2 lesions did not show any pathological finding. At 18F-NaF PET/CT, the 19 bone lesions detected at 18F-FDG PET/TC also demonstrated abnormal tracer uptake, and the other 2 bone iodine avid foci did not show any pathological finding.
CONCLUSIONS: In patients with DTC, 18F-NaF PET/CT did not obtain more information on the metastatic skeletal involvement than post-therapy 131I WBS and 18F-FDG PET/CT.
摘要：
背景：分化型甲状腺癌（DTC）患者接受放射性131I（RAI）治疗和治疗后131I全身闪烁显像（WBS）以确定局部和/或远端转移。这些患者也可以使用具有18F-氟-D-葡萄糖（FDG）或18F-氟化钠（NaF）的正电子发射断层扫描（PET）/计算机断层扫描（CT）成像来评估骨转移。我们比较了18F-NaFPET/CT和18F-FDG-PET/CT在DTC患者中的作用，并记录了治疗后WBS的骨转移。
方法：研究了10例连续接受18F-NaFPET/CT和18F-FDGPET/CT的WBS治疗后出现碘性骨转移的DTC患者。比较了三种成像程序的异常检出率和一致性。
结果：治疗后131IWBS，所有患者均有骨骼受累,共发生21例骨碘狂热病变.在18F-FDGPET/TC，19个骨病变显示示踪剂摄取增加和CT病理改变，而2个病灶未显示任何病理发现。在18F-NaFPET/CT,在18F-FDGPET/TC检测到的19个骨病变也显示出异常的示踪剂摄取，另外2个骨碘狂热病灶未显示任何病理发现。
结论：在DTC患者中，与治疗后131IWBS和18F-FDGPET/CT相比，18F-NaFPET/CT并未获得更多有关转移性骨骼受累的信息。
方法：研究了10例连续接受18F-NaFPET/CT和18F-FDGPET/CT的WBS治疗后出现碘性骨转移的DTC患者。比较了三种成像程序的异常检出率和一致性。
结果：治疗后131IWBS，所有患者均有骨骼受累,共发生21例骨碘狂热病变.在18F-FDGPET/TC，19个骨病变显示示踪剂摄取增加和CT病理改变，而2个病灶未显示任何病理发现。在18F-NaFPET/CT,在18F-FDGPET/TC检测到的19个骨病变也显示出异常的示踪剂摄取，另外2个骨碘狂热病灶未显示任何病理发现。
结论：在DTC患者中，与治疗后131IWBS和18F-FDGPET/CT相比，18F-NaFPET/CT并未获得更多有关转移性骨骼受累的信息。
